Anna R. Giuliano, Ph.D., Joel M. Palefsky, M.D., Stephen Goldstone, M.D., Edson D. Moreira, Jr., M.D., Mary E. Penny, M.D., Carlos Aranda, M.D., Eftyhia Vardas, M.D., Harald Moi, M.D., Heiko Jessen, M.D., Richard Hillman, M.D., Yen-Hwa Chang, M.D., Daron Ferris, M.D., Danielle Rouleau, M.D., Janine Bryan, Ph.D., J. Brooke Marshall, Ph.D., Scott Vuocolo, Ph.D., Eliav […]
Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection A Randomized Trial
JAMA. 2007;298:743-753. Main Outcome Measures Presence of HPV DNA was determinedin cervical specimins by a molecular hybridization assay usingchemiluminescence with HPV RNA probes and by polymerase chainreaction using SPF10 primers and a line probe assay detectionsystem before vaccination and by polymerase chain reaction aftervaccination. We compared rates of type-specific viral clearanceusing generalized estimating equations methods at […]
Confirmation Of High Efficacy Of HPV Vaccine Against Precancerous Cervical Lesions And Protective Effect Of Vaccination Programs
Article Date: 07 Jul 2009 – 0:00 PDT The findings of the PATRICIA study are reported in an article Online First and in a future edition of The Lancet. It shows that the HPV-16/18 AS04-adjuvanted vaccine (GlaxoSmithKline) has high efficacy against the precancerous cervical lesions that can eventually lead to cervical cancer. There is confirmation […]
Prophylactic HPV Vaccines: Current Knowledge of Impact on Gynecological Premalignancies
Authors: Diane M. Harper/Karen B. Williams Published 3 July 2010, Discovery Medicine Abstract: Approaches for cervical cancer prevention are changing. Screening still remains the most effective method for cervical cancer prevention. Guidelines are moving to an older group of women to be screened less frequently with combinations of technologies that include biomarkers and cytology. HPV […]
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24—45 years: a randomised, double-blind trial
The Lancet, Volume 373, Issue 9679, Pages 1949 – 1957, 6 June 2009 doi:10.1016/S0140-6736(09)60691-7: Munoz, et al Background: Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5—10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and […]